Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ.

Mol Cancer Ther. 2012 Oct;11(10):2243-53. doi: 10.1158/1535-7163.MCT-12-0135. Epub 2012 Aug 28.

2.

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ.

Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29.

3.

The immunoproteasome as a target in hematologic malignancies.

Kuhn DJ, Orlowski RZ.

Semin Hematol. 2012 Jul;49(3):258-62. doi: 10.1053/j.seminhematol.2012.04.003. Review.

4.

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

Kuhn DJ, Orlowski RZ, Bjorklund CC.

Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. Review.

PMID:
21247387
5.

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ.

Br J Haematol. 2011 Mar;152(5):579-92. doi: 10.1111/j.1365-2141.2010.08533.x. Epub 2011 Jan 17.

6.

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ.

J Biol Chem. 2011 Apr 1;286(13):11009-20. doi: 10.1074/jbc.M110.180208. Epub 2010 Dec 28.

7.

Bortezomib and EGCG: no green tea for you?

Shah JJ, Kuhn DJ, Orlowski RZ.

Blood. 2009 Jun 4;113(23):5695-6. doi: 10.1182/blood-2009-03-204776. No abstract available.

8.

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ.

Br J Haematol. 2009 May;145(4):481-90. doi: 10.1111/j.1365-2141.2009.07647.x. Epub 2008 Mar 6.

9.

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ.

Blood. 2009 May 7;113(19):4667-76. doi: 10.1182/blood-2008-07-171637. Epub 2008 Dec 2.

10.

Proteasome inhibitors in cancer therapy: lessons from the first decade.

Orlowski RZ, Kuhn DJ.

Clin Cancer Res. 2008 Mar 15;14(6):1649-57. doi: 10.1158/1078-0432.CCR-07-2218. Review.

11.

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ.

Blood. 2008 May 1;111(9):4690-9. doi: 10.1182/blood-2007-09-112904. Epub 2008 Feb 27.

12.

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.

Clin Cancer Res. 2007 Nov 1;13(21):6469-78.

13.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

14.

Methylation suppresses the proteasome-inhibitory function of green tea polyphenols.

Landis-Piwowar KR, Wan SB, Wiegand RA, Kuhn DJ, Chan TH, Dou QP.

J Cell Physiol. 2007 Oct;213(1):252-60.

PMID:
17477351
15.

Anti-angiogenic and anti-tumor properties of proteasome inhibitors.

Daniel KG, Kuhn DJ, Kazi A, Dou QP.

Curr Cancer Drug Targets. 2005 Nov;5(7):529-41. Review.

PMID:
16305349
16.

Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.

Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR, Dou QP.

Biochem Pharmacol. 2005 May 15;69(10):1421-32.

PMID:
15857606
18.

The role of interleukin-2 receptor alpha in cancer.

Kuhn DJ, Dou QP.

Front Biosci. 2005 May 1;10:1462-74. Review.

PMID:
15769637
19.

Structure-activity relationships OF N-methylthiolated beta-lactam antibiotics with C3 substitutions and their selective induction of apoptosis in human cancer cells.

Kuhn DJ, Wang Y, Minic V, Coates C, Reddy GS, Daniel KG, Shim JY, Chen D, Landis-Piwowar KR, Miller FR, Turos E, Dou QP.

Front Biosci. 2005 May 1;10:1183-90.

PMID:
15769617
20.

Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs.

Landis-Piwowar KR, Kuhn DJ, Wan SB, Chen D, Chan TH, Dou QP.

Int J Mol Med. 2005 Apr;15(4):735-42.

PMID:
15754040
21.

Structure-activity study of epi-gallocatechin gallate (EGCG) analogs as proteasome inhibitors.

Wan SB, Landis-Piwowar KR, Kuhn DJ, Chen D, Dou QP, Chan TH.

Bioorg Med Chem. 2005 Mar 15;13(6):2177-85.

PMID:
15727870
22.

A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG].

Lam WH, Kazi A, Kuhn DJ, Chow LM, Chan AS, Dou QP, Chan TH.

Bioorg Med Chem. 2004 Nov 1;12(21):5587-93.

PMID:
15465336
23.

Green tea and tea polyphenols in cancer prevention.

Chen D, Daniel KG, Kuhn DJ, Kazi A, Bhuiyan M, Li L, Wang Z, Wan SB, Lam WH, Chan TH, Dou QP.

Front Biosci. 2004 Sep 1;9:2618-31. Review.

PMID:
15358585
25.

Novel N-thiolated beta-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells.

Kazi A, Hill R, Long TE, Kuhn DJ, Turos E, Dou QP.

Biochem Pharmacol. 2004 Jan 15;67(2):365-74.

PMID:
14698048
26.

A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells.

Kazi A, Urbizu DA, Kuhn DJ, Acebo AL, Jackson ER, Greenfelder GP, Kumar NB, Dou QP.

Int J Mol Med. 2003 Dec;12(6):879-87.

PMID:
14612961

Supplemental Content

Support Center